Latest Breaking News On - Arshadm khanani - Page 8 : comparemela.com

Ophthalmology Month in Review: November 2023

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our November 2023 month-in-review features a trio of FDA news, important updates to the GA pipeline, and insight into disparities in eye care.

United statesDurga borkarArshadm khananiRite aidDuke eye centerSierra eye associatesAmerican academy of ophthalmologyOcuphire pharma incKilitch healthcare indiaDrug administrationIntelligent research in sightAnnual american academyKilitch healthcare india limitedOcuphire pharmaSpecial protocol assessmentComplete response letter

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

Initial interim landmark data analysis to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET .

United statesKatherine smithArshadm khananiJulian peiReno school of medicineClinical associate professor at university of nevadaCorporate communicationsClinical research at sierra eye associatesPrincipal investigatorMolecular therapeuticsDose expansionDegeneration presentation detailsInterim resultsRandomized phaseExpansion stageHigh need patients

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesArshadm khananiKatherine smithJulian peiCorporate communicationsClinical associate professor at university of nevadaClinical research at sierra eye associatesReno school of medicinePresent interimRandomized phaseHigh treatment need wetPrincipal investigatorMolecular therapeuticsDose expansionDegeneration presentation detailsInterim results

Arshad Khanani, MD: Two-Year Results from GATHER2 Trial

Phase 3 results from the GATHER2 trial show the treatment effect of avacincaptad pegol for geographic atrophy more than doubled over 2 years compared to year 1 of study.

United statesSan franciscoArshadm khananiAmerican academy of ophthalmologyDrug administrationSierra eye associatesEuropean medicines associationAnnual american academyEuropean medicines

IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years

Phase 3 results presented at the AAO Annual Meeting demonstrated the IZERVAY treatment effect more than doubled over 2 years compared to 1 yearIZE.

United statesSan franciscoIveric bioArshadm khananiDhaval desaiNaoki okamuraAstellas companyAmerican academy of ophthalmologyDrug administration onClinical research at sierra eye associatesAstellas pharma incEuropean medicines agencyAstellas pharmaAmerican academyClinical researchSierra eye associates